PERINDOPRIL ERBUMINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H32N2O5.C4H11N
Molecular Weight	441.6046
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)N.[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O

InChI

InChIKey=IYNMDWMQHSMDDE-MHXJNQAMSA-N

InChI=1S/C19H32N2O5.C4H11N/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;1-4(2,3)5/h12-16,20H,4-11H2,1-3H3,(H,23,24);5H2,1-3H3/t12-,13-,14-,15-,16-;/m0./s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020184s022lbl.pdfhttp://pubs.rsc.org/-/content/getauthorversionpdf/C3AY42056Fhttps://www.ncbi.nlm.nih.gov/pubmed/1457697http://www.hmdb.ca/metabolites/HMDB60574
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1718688

Perindoprilat is a metabolite of perindopril. Perindopril is a long-acting angiotensin converting enzyme (ACE) inhibitor and it is used to treat high blood pressure, heart failure or stable coronary artery disease. Perindopril is designed to allow oral administration as perindoprilat is poorly absorbed from the gastrointestinal tract.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin-converting enzyme 97 Target ID: CHEMBL1808 Sources: http://www.hmdb.ca/metabolites/HMDB60574	Inhibitor 8297		1.05 nM [IC50]
Angiotensin-converting enzyme 97 Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17716647	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Unknown 2578
Stable coronary artery disease 7 Sources: https://www.drugs.com/pro/perindopril.html	Primary	Approved 8429	ACEON Approved Use Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Launch Date 1993
Hypertension 567 Sources: https://www.drugs.com/pro/perindopril.html	Primary	Approved 8429	ACEON Approved Use Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. Launch Date 1993
Parkinson's disease 226 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10800878	Palliative	Not Provided 504	Unknown Approved Use Unknown
Unknown 2578

C_max

Value	Dose	Co-administered	Analyte	Population
83.83 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.54 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
130 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
170.61 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
38.01 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
40% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
80% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12076191/	unhealthy, adult n = 320 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 320 Sources: https://pubmed.ncbi.nlm.nih.gov/12076191/	Disc. AE: Cough... AEs leading to discontinuation/dose reduction: Cough (2.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/12076191/

AEs

AE	Significance	Dose	Population
Cough	2.8% Disc. AE	4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12076191/	unhealthy, adult n = 320 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 320 Sources: https://pubmed.ncbi.nlm.nih.gov/12076191/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2J2 16	UGT 192 CYP 270	CYP 76

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 147	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/15449971/	no
CYP2J2 19	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/pii/S0009279719303631	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 270	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15449971/	no
UGT 192	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020184s023lbl.pdf#page=9 Page: 9.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:132041	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:132041
ChemicalBook	CB0240343	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0240343
MolPort	MolPort-006-395-652	https://www.molport.com/shop/molecule-link/MolPort-006-395-652
ZINC	ZINC000004217270	http://zinc15.docking.org/substances/ZINC000004217270
eMolecules	36754394	https://www.emolecules.com/cgi-bin/more?vid=36754394

PubMed

Title	Date	PubMed
Challenges for the prevention of primary and secondary stroke: the importance of lowering blood pressure and total cardiovascular risk.	2001	11822538
[Effects of angiotensin-converting enzyme inhibitors and cosaar on quality of life of patients with pulmonary tuberculosis and chronic heart failure].	2001	11767390
Interventions for deliberately altering blood pressure in acute stroke.	2001	11686949
[Hypotension followed the first dose of angiotensin-converting enzyme inhibitor in patients with heart failure (a multicenter clinical trial)].	2001	11642085
[Effects of perindopril and its combination with indapamide on risk stratification in patients with hypertension].	2001	11642074
[The comparison of clinical effectiveness of perindopril and acebutolol in the primary hypertension treatment].	2001	11603173
Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics.	2001 Aug	11685903
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol.	2001 Aug	11685901
Academic support for combination therapy in hypertension.	2001 Aug-Sep	11766616
Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins.	2001 Dec	11795271
ACE inhibitors in vascular disease: some PROGRESS, more HOPE.	2001 Dec	11773984
Chronic ACE inhibition enhances the endothelial control of arterial mechanics and flow-dependent vasodilatation in heart failure.	2001 Dec 1	11751733
The lowering of blood pressure after stroke.	2001 Dec 8	11747948
The lowering of blood pressure after stroke.	2001 Dec 8	11747946
The lowering of blood pressure after stroke.	2001 Dec 8	11747945
The lowering of blood pressure after stroke.	2001 Dec 8	11747944
The lowering of blood pressure after stroke.	2001 Dec 8	11747943
Assessment of perindopril's efficacy on arterial distensibility in mild to moderate hypertension.	2001 Jul	11759959
Coversyl plus--when monotherapy is not enough.	2001 Jun-Jul	11710312
New benefits of blood pressure lowering treatments for millions of stroke sufferers.	2001 Jun-Jul	11710310
The EUROPA trial: design, baseline demography and status of the substudies.	2001 Mar	11669411
Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension.	2001 Nov	11848262
Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination.	2001 Nov	11848258
[Clinical study of the month. Secondary prevention of cerebrovascular accident with perindopril: the PROGRESS study].	2001 Nov	11789395
[Early prevention of experimental left ventricular hypertrophy in experimental hypertension and angiotensin II levels].	2001 Nov	11707239
Effect of angiotensin-converting enzyme inhibition on renal filtration surface area in hypertensive rats.	2001 Nov	11703601
Does ACE inhibition slow progression of glomerulopathy in patients with Type 2 diabetes mellitus?	2001 Nov	11703440
Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus.	2001 Nov	11699055
Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats.	2001 Nov	11684080
Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake.	2001 Nov	11677376
[Efficacy of a converting enzyme inhibitor in the prevention of recurrence of stroke].	2001 Nov 24	11775593
A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy.	2001 Oct	11806464
Increased absorption of zinc from alimentary tract in primary arterial hypertension.	2001 Oct	11694000
Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol.	2001 Oct	11641310
Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway.	2001 Oct 12	11597990
Safety profile of perindopril.	2001 Oct 4	11591359
Effects of perindopril on cardiovascular remodeling.	2001 Oct 4	11591358
Dietary n-3 polyunsaturated fatty acids affect the development of renovascular hypertension in rats.	2001 Sep	11716352
Very-low-dose combination of perindopril and indapamide as a novel strategy in first-line management of hypertension.	2001 Sep	11713850
Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.	2001 Sep	11596665
Identification and determination of selected medicines reducing hypertension by densitometric and gas chromatographic methods.	2001 Sep-Oct	11876439
[Antihypertensive agents after cerebral stroke are more effective than expected].	2001 Sep-Oct	11845587
Detection of coronary microvascular disease by means of cardiac scintigraphy.	2002 Feb	11875588
Progress in secondary prevention of stroke with PROGRESS. The perindopril protection against recurrent stroke study.	2002 Feb	11790290
Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease.	2002 Jan	11855668
Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.	2002 Jan	11786082
The PROGRESS Trial: preventing strokes by lowering blood pressure in patients with cerebral ischemia. Emerging therapies: critique of an important advance.	2002 Jan	11779934
Comparison of perindopril versus captopril for treatment of acute myocardial infarction.	2002 Jan 15	11792333
Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats.	2002 Mar	11856772
Combined therapy with indapamide and perindopril but not perindopril alone reduced the risk for recurrent stroke.	2002 Mar-Apr	11874276

Patents

Sample Use Guides

In Vivo Use Guide

In patients with essential hypertension, the recommended initial dose is 4 mg once a day. The dose may be titrated, as needed to a maximum of 16 mg per day. The usual maintenance dose range is 4 mg to 8 mg administered as a single daily dose or in two divided doses. In patients with stable coronary artery disease, Perindopril erbumine tablets should be given at an initial dose of 4 mg once daily for 2 weeks, and then increased as tolerated, to a maintenance dose of 8 mg once daily. In elderly patients (greater than 70 years), Perindopril erbumine tablets should be given as a 2 mg dose once daily in the first week, followed by 4 mg once daily in the second week and 8 mg once daily for maintenance dose if tolerated.

Route of Administration: Oral

In Vitro Use Guide

Perindoprilat (S-9780), the major metabolite of perindopril, inhibited guinea pig plasma angiotensin-converting enzyme (ACE) by 50% (IC50) at a concentration of 2.4 +/- 0.1 nM. A Ki of 1.2 nM was obtained for S-9780 (Dixon-Webb plot) with angiotensin I as a substrate.

Name

Type

Language

PERINDOPRIL ERBUMINE

Official Name

English

PERINDOPRIL ERBUMINE [MART.]

Common Name

English

PERINDOPRIL TERT-BUTYLAMINE [EP MONOGRAPH]

Common Name

English

PERINDOPRIL ERBUMINE [USAN]

Common Name

English

PERINDOPRIL ERBUMINE [USP MONOGRAPH]

Common Name

English

Perindopril erbumine [WHO-DD]

Common Name

English

AMLESSA COMPONENT PERINDOPRIL ERBUMINE

Common Name

English

PERINDOPRIL T-BUTYLAMINE

Common Name

English

PERINDOPRIL ERBUMINE [ORANGE BOOK]

Common Name

English

S-9490-3

Code

English

ACEON

Brand Name

English

MCN-A-2833-109

Code

English

NSC-758929

Code

English

(2S,3aS,7aS)-1-[(S)-N-[(S)-1-Carboxybutyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester, compound with tert-butylamine (1:1)

Common Name

English

1H-INDOLE-2-CARBOXYLIC ACID, 1-(2-((1-(ETHOXYCARBONYL)BUTYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, (2S-(1(R*(R*)),2.ALPHA.,3A.BETA.,7A.BETA.))-, COMPD. WITH 2-METHYL-2-PROPANAMINE (1:1)

Common Name

English

PERINDOPRIL TERT-BUTYLAMINE

Common Name

English

PERINDOPRIL ERBUMINE [VANDF]

Common Name

English

PERINDOPRIL ERBUMINE [JAN]

Common Name

English

PERINDOPRIL ERBUMINE [USP-RS]

Common Name

English

PERINDOPRIL TERT-BUTYLAMINE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C247

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

Code System Code Type Description

MERCK INDEX

m8555

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

Merck Index

RXCUI

72260

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

RxNorm

SMS_ID

100000091602

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

USAN

AA-67

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

EPA CompTox

DTXSID1044198

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

EVMPD

SUB03711MIG

Created by admin on Fri Dec 15 15:40:33 GMT 2023 , Edited by admin on Fri Dec 15 15:40:33 GMT 2023

PRIMARY

DRUG BANK

DB00790

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

RS_ITEM_NUM

1510889

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

CAS

107133-36-8

Created by admin on Fri Dec 15 15:40:33 GMT 2023 , Edited by admin on Fri Dec 15 15:40:33 GMT 2023

PRIMARY

NSC

758929

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

PUBCHEM

441313

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

CHEBI

8025

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

ChEMBL

CHEMBL1581

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

NCI_THESAURUS

C47666

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

DAILYMED

1964X464OJ

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

FDA UNII

1964X464OJ

Created by admin on Fri Dec 15 15:40:34 GMT 2023 , Edited by admin on Fri Dec 15 15:40:34 GMT 2023

PRIMARY

ACTIVE MOIETY


					2UV6ZNQ92K

PERINDOPRILAT

PARENT (SALT/SOLVATE)


					91Z53KF68U

ERBUMINE

PARENT (SALT/SOLVATE)


					Y5GMK36KGY

PERINDOPRIL

SUBSTANCE RECORD


					1964X464OJ

PERINDOPRIL ERBUMINE

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator